Evaxion Biotech (EVAX) has released an update.
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Evaxion Biotech has received a delisting determination from Nasdaq due to insufficient stockholder equity but has appealed the decision and requested a hearing to seek an additional 180-day extension. The company remains committed to maintaining its Nasdaq listing by increasing equity through business development and capital market activities. Despite challenges in the current market environment, Evaxion is in ongoing discussions with Nasdaq to regain compliance.
For further insights into EVAX stock, check out TipRanks’ Stock Analysis page.
